Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.48 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.48 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.48 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12489574 | 0.82 | ALDH2 (0.48) | CDK9DYRK1ADYRK2MAPTATM | |
| SCHEMBL1610145 | 0.80 | MAPT (0.50) | MAPTATMKCNH2KMT2ANPC1 | |
| SCHEMBL15724651 | 0.78 | MAPT (0.47) | MAPTATMKCNH2KMT2ANPC1 | |
| SCHEMBL14409919 | 0.78 | MCL1 (0.59) | CDK9DYRK1ADYRK2ALDH2ALDH1A2 | |
| SCHEMBL12301447 | 0.78 | LMNA (0.51) | CDK9DYRK1ADYRK2MAPTALDH2 | |
| SCHEMBL3894812 | 0.78 | CDK9 (0.50) | CDK9DYRK1ADYRK2MAPTALDH2 | |
| SCHEMBL12301578 | 0.78 | CDK9 (0.50) | CDK9DYRK1ADYRK2MAPTALDH2 | |
| SCHEMBL13024730 | 0.78 | MAPT (0.47) | MAPTATMNPC1HTTALDH1A1 | |
| SCHEMBL8229629 | 0.78 | CDK9 (0.59) | CDK9DYRK1ADYRK2MAPTALDH2 | |
| SCHEMBL4570872 | 0.78 | NQO1 (0.57) | MAPTALDH2ALDH1A2ALDH1B1ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212207-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212207-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210155647-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-05-27 | — | — | US | disclosed |
| US-9238636-B2 | Process for preparation of dronedarone by Grignard reaction | SANOFI (FR) | 2016-01-19 | — | — | US | disclosed |
| US-20150274688-A1 | PROCESS FOR PREPARATION OF DRONEDARONE BY GRIGNARD REACTION | SANOFI (FR) | 2015-10-01 | — | — | US | disclosed |
| US-8202871-B2 | Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-06-19 | — | — | US | disclosed |
| US-8202871-B2 | Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-06-19 | — | — | US | disclosed |
| EP-2188253-B1 | Indol-2-one derivatives disubstituted in 3-position, preparation thereof and therapeutic use thereof | SANOFI SA (FR) | 2012-03-07 | — | — | EP | disclosed |
| US-20110118280-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118280-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | US | disclosed |
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | US | disclosed |
| US-20090023747-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-7169931-B2 | Cell differentiation, cell proliferation | SHIONOGI & CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| US-7169931-B2 | Cell differentiation, cell proliferation | SHIONOGI & CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, IDO1, TPH2 | CDK9 621/4885DYRK1A 177/4885DYRK2 76/4885 |
| US-20090023747-A1 | Cysteine Protease Inhibitors | CTSK, CTSS, CTSZ | CDK9 1240/4885DYRK1A 3482/4885DYRK2 3369/4885 |
| US-20230212207-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OTC, OCIAD1 | CDK9 2845/4885DYRK1A 4681/4885DYRK2 4659/4885 |
| US-20150274688-A1 | PROCESS FOR PREPARATION OF DRONEDARONE BY GRIGNARD REACTION | CYP3A4, CYP2C9, CYP4B1 | CDK9 2308/4885DYRK1A 1836/4885DYRK2 1964/4885 |
| US-20110118280-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, IDO1, TPH2 | CDK9 621/4885DYRK1A 177/4885DYRK2 76/4885 |
| US-20210155647-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND | NOM1, MSL1, L1CAM | CDK9 1749/4885DYRK1A 4573/4885DYRK2 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.